Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Open-Label, Multicenter Study Comparing CM336 Monotherapy vs. Investigators Selected Standard of Care in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received ≥2 Prior Lines of Therapy

NCT07181239 is registered in ClinicalTrials.gov with Keymed Biosciences Co.Ltd as lead sponsor.

NCT NCT07181239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07181239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Open-Label, Multicenter Study Comparing CM336 Monotherapy vs. Investigators Selected Standard of Care in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received ≥2 Prior Lines of Therapy
Lead sponsor
Keymed Biosciences Co.Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 30, 2025
Completion date
April 30, 2030
Enrollment
280 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma (mm)